Companies featured in this edition of the newsletter: ACTC, CUR, CVM, DKAM, ENZ, IMUC, MFGD, NXOI, OMCM, ONEZ, PSID, XSNX

Markets continued to carry momentum during the early stages of last week, as the absence of significant economic news led to a continuation of the upward trend characterizing the past few weeks, until an earnings miss from Dell on Thursday led to a selloff in the technology sector which caused the major indices to end the week mixed. All told, the Dow ended the week in positive territory, gaining 47 points to close at 10318, up 0.5% on the week and 17.6% on the year. The Nasdaq surrendered 1.0% to close at 2146, paring its YTD gains to 36.1%, while the S&P 500 and Russell 2000 lost 0.2% and 0.3% respectively, reducing their yearly gains to 20.8 and 17.1.

Things got off to a strong start on Monday, with the

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Thursday November 12, 2009

DrStockPick.com Stock Report!

COV, PWRM

**************************************************************

COV, Covidien Plc

COV is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. COV manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies.

COV launched DuraSeal™ spine sealant, the first product approved by the U.S. Food and Drug Administration (FDA) for intra-operative sealing of the dural membrane during spine procedures. Nearly 1.5 million spine surgeries are performed in the U.S. every year, with an estimated 10% of these

CNS Response Inc. has developed a data analysis capability that, when paired with a non-invasive EEG, analyzes a patient’s brain waves and compares those results to a patient outcome database, generating an rEEG report that allows psychiatrists to create personalized medication regimens for the patient.

According to the company, depression costs U.S. employers $83 billion annually; more than half of these costs are associated with treatment-resistant depression. Individuals with treatment-resistant depression cost $8,500 more per year than patients with ordinary depression. Through various studies, rEEG is the first objective, physiology-based, personalized medical technologies proven to efficiently and consistently enable psychiatrists to determine the right treatment for patients.

CNS Response today announced that Charles DeBattista, D.M.H, M.D., will present the results of a recent landmark study of rEEG at the U.S. Psychiatric and Mental Health Congress. The study proved rEEG effective at predicting medication response approximately 65 percent of the time.

Pluristem Therapeutics works to commercialize cellular bio-therapies for the treatment of several degenerative, ischemic and autoimmune conditions. In a release that was largely overlooked last week, Pluristem conveyed the success of recent clinical trials, showing the pronounced effectiveness of its PLacental eXpanded (PLX) cells in treating Inflammatory Bowel Disease (IBD).

Pluristem defines its PLX product as mesenchymal stromal cells (MSCs) that have been expanded using the company’s proprietary PluriX™ 3-D bioreactor. Basically, MSCs are undifferentiated, protoplasmic placental cells.

In the study conducted, mice which were afflicted with IBD were administered PLX cells intrarectally, while a control group was treated with a saline solution. Pluristem’s treatment was shown to greatly reduce colon lesions associated with IBD in both macroscopic and microscopic evaluations, as compared to the control subjects.

Pluristem President and CEO, Zami Aberman stated: “This trial’s favorable results, which demonstrate our PLX cells’ ability to treat Inflammatory Bowel Disease, as